Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study

Conference Reports for NATAP

IAS
25th International AIDS Conference
22 to 26 July 2024


Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study

	AIDS 2024 July 20-26 Munich